Assuming patients is required, the following results were found.

  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) DetailsHits: 158If approved, Mayzent® (siponimod) will be the first and only oral treatment...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    and immunopathogenesis and instead share some clinical pearls to help both simplify and advance your care for patients and families affected by MS. My goal is to share a simple approach that will serve you and your patients well, with the aim of helping...

    https://mschristian.org/index.php/blog/treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    (MRI). Question Addressed: What was the rate of stroke defined by diffusion restriction detected on MRI scans among patients with low-risk suspected transient ischemic attack (TIA) or minor stroke presentations? Study Synopsis and Perspective: Patients...

    https://mschristian.org/index.php/blog/doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    Inc., (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the third quarter of 2019 and recent...

    https://mschristian.org/index.php/blog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Rethinking neurodegenerative disease treatment: Target multiple pathological proteins

    all of the different neurodegenerative disorders and may instigate each other to drive disease severity in many aging patients. The prevalence of these co-pathologies suggests that each disease may ultimately require combination therapy targeting...

    https://mschristian.org/index.php/blog/rethinking-neurodegenerative-disease-treatment-target-multiple-pathological-proteins
  • Short-Duration Opioid Protocol Feasible for Tonsillectomy

    within the first year after surgery, a retrospective analysis of active-duty military personnel showed. Of almost 700 patients who received as much as a 15-day postoperative prescription of opioid-containing medication, none had a referral for treatment...

    https://mschristian.org/index.php/blog/short-duration-opioid-protocol-feasible-for-tonsillectomy
  • Suicide Rate Almost Double in Patients With MS

    BARCELONA — Patients with multiple sclerosis (MS) are more than twice as likely as the general population to attempt suicide and almost twice as likely to actually complete suicide, a new study shows. The study also had some interesting results with...

    https://mschristian.org/index.php/blog/suicide-rate-almost-double-in-patients-with-ms
  • Prescription digital therapeutics: reimagining disease treatment - STAT

    clinicians, and engineers working in tandem to leverage the power of software to treat disease. They are designed so patients can access treatment when and where they need it. Similar to traditional medicines, PDTs are prescribed by physicians and...

    https://mschristian.org/index.php/blog/prescription-digital-therapeutics-reimagining-disease-treatment-stat
  • Neurology group updates vaccine recommendations for patients with MS - Pharmacy Today, American Pharmacists Association, pharmacist.com

    with MS should feel safe and comfortable getting their recommended vaccinations.” The updated guideline recommends that patients with MS follow all local vaccine standards, as stated by CDC, the World Health Organization, and other local regulatory...

    https://mschristian.org/index.php/blog/neurology-group-updates-vaccine-recommendations-for-patients-with-ms-pharmacy-today-american-pharmacists-association-pharmacist-com
  • MS Patients Have Low Blood Levels of Infection-fighting Antibodies, Study Finds - Multiple Sclerosis News Today

    infection. Because many MS therapies work by decreasing the activity of the immune system, it is possible that treated patients have abnormally low levels of certain kinds of antibodies and, as a result, become more prone to infection. A team led by...

    https://mschristian.org/index.php/blog/ms-patients-have-low-blood-levels-of-infection-fighting-antibodies-study-finds-multiple-sclerosis-news-today
  • How MS Affects Sleep Quality - Plus: Sleep Tips for People with Multiple Sclerosis

    Some MS medications have side effects that impact sleep. 3. Frequent urge to urinate: It’s not uncommon for MS patients to experience an increased need to urinate. During the nighttime, this can lead to waking up frequently during the night. 4. Muscle...

    https://mschristian.org/index.php/blog/how-ms-affects-sleep-quality-plus-sleep-tips-for-people-with-multiple-sclerosis
  • Dr. Brian Cole Implements New Wound Closure Innovation To Ease And Improve Healing - P&T Community

    fast and minimally invasive way to heal. Dr. Brian Cole, MBA, MOR Managing Partner, now uses the product for his surgical patients. "Patient-centered care is of paramount importance to me, and BandGrip addresses many of the concerns my patients have,"...

    https://mschristian.org/index.php/blog/dr-brian-cole-implements-new-wound-closure-innovation-to-ease-and-improve-healing-p-t-community
  • Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    WIRE)-- – Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with patients who started Ocrevus after the...

    https://mschristian.org/index.php/blog/genentech-presents-new-six-year-ocrevus-ocrelizumab-data-which-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis
  • PTAC OKs Model to Boost Stroke Care at Rural Hospitals

    WASHINGTON -- A telemedicine-based payment model to improve care for patients experiencing stroke and other cerebral emergencies in rural, underserved communities won support from the Physician-Focused Payment Model Technical Advisory Committee (PTAC)....

    https://mschristian.org/index.php/blog/ptac-oks-model-to-boost-stroke-care-at-rural-hospitals
  • Potential genetic markers of multiple sclerosis severity

    single out these genes -- known to be integral in the development of the brain and immune systems -- by using DNA from MS patients along with high-tech retinal scanning. If further studies confirm the researcher's findings, reported in the September...

    https://mschristian.org/index.php/blog/potential-genetic-markers-of-multiple-sclerosis-severity
  • Can Anti-TNF Drugs Reduce Alzheimer's Risk?

    diseases involving tumor necrosis factor (TNF) increased the risk of Alzheimer's disease, but that risk was reduced in patients who used anti-TNF biologics, an analysis of 56 million adults' electronic health records showed. While rheumatoid arthritis...

    https://mschristian.org/index.php/blog/can-anti-tnf-drugs-reduce-alzheimer-s-risk
  • In tiny doses, an addiction medication moonlights as treatment for chronic pain

    she said. “I hate opioids with a passion,” Pinkley said. “An absolute passion.” Recently she joined a growing group of patients using an outside-the-box remedy: naltrexone. It is typically used to treat addiction to opioids or alcohol, in pill form or...

    https://mschristian.org/index.php/blog/in-tiny-doses-an-addiction-medication-moonlights-as-treatment-for-chronic-pain
  • #ECTRIMS2019 - Mayzent's Benefits for MS Patients a 'Key Question,' Says EXPAND's Principal Investigator - Multiple Sclerosis News Today

    Data from the EXPAND study (NCT01665144) was one of the key pieces of evidence for Mayzent’s approval. Involving 1,651 patients with SPMS (both active and non-active), the study showed that taking 2 mg tablets of Mayzent once per day reduced the risk of...

    https://mschristian.org/index.php/blog/ectrims2019-mayzent-s-benefits-for-ms-patients-a-key-question-says-expand-s-principal-investigator-multiple-sclerosis-news-today
  • EMA committee recommends caution in use of tofacitinib owing to increased risk of blood clots - The Pharmaceutical Journal

    tofacitinib (Xeljanz; Pfizer) could increase the risk of blood clots in the lungs and should be used with caution in all patients already at high risk. Tofacitinib is indicated for moderate-to-severe active rheumatoid arthritis (RA) in patients who have...

    https://mschristian.org/index.php/blog/ema-committee-recommends-caution-in-use-of-tofacitinib-owing-to-increased-risk-of-blood-clots-the-pharmaceutical-journal
  • New treatment shows promise to reverse celiac disease

    to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet. After treatment with the technology, the patients were able to eat gluten...

    https://mschristian.org/index.php/blog/new-treatment-shows-promise-to-reverse-celiac-disease

Results 1 - 20 of 150
 
 

Follow Us on Twitter

Follow Us On Twitter - Image